Urticarial vasculitis is an autoimmune condition that causes itchy or painful hives. Some people may also develop inflammation in other organs, such as the kidneys or lungs. Vasculitis is a group of ...

Patients with CSU have an elevated risk of anxiety and depression, necessitating comprehensive management strategies. Research is focused on identifying biomarkers and clinical characteristics to ...

Novartis announced that the European Commission (EC) approved Rhapsido (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1-antihistamine treatment.

Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of ...

Rilzabrutinib significantly alleviates itch and hives in patients with CSU unresponsive to H1-antihistamines, offering a potential new treatment option. The RILECSU trial demonstrated significant ...

Sponsored by Novartis Pharmaceuticals Corporation, and Emmeka and Dr. Gupta were compensated by Novartis. Emmeka is a 28-year-old Iowa-based social media manager and beauty content creator, who began ...

EAST HANOVER, N.J., Sept. 30, 2025 /PRNewswire/ -- Novartis announced today that Rhapsido ® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Rhapsido (remibrutinib) is a prescription medicine used to treat adults with chronic spontaneous urticaria (CSU). This is a condition that involves hives, causing you to feel very itchy and ...

Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1Rhapsido recommended in 2026 International Urti ...